Disease Information

General Information of the Disease (ID: DIS00231)

• Name: Lupus erythematosus
• ICD: ICD-11: 4A40

Type(s) of Resistant Mechanism of This Disease

  IDUE: Irregularity in Drug Uptake and Drug Efflux

Drug Resistance Data Categorized by Drug

Approved Drug(s) 1 drug(s) in total

Methotrexate

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Irregularity in Drug Uptake and Drug Efflux (IDUE)

Key Molecule: Multidrug resistance protein 1 (ABCB1) [1]

• Resistant Disease: Systemic lupos erythematosus [ICD-11: 4A40.2]
• Molecule Alteration: Expression; Up-regulation
• Resistant Drug: Methotrexate
• Experimental Note: Identified from the Human Clinical Data
• Mechanism Description: Up-regulation of P-glycoprotein led to methotrexate resistance in the staphylococcus infection.

Investigative Drug(s) 1 drug(s) in total

Corticosteroids

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Irregularity in Drug Uptake and Drug Efflux (IDUE)

Key Molecule: Multidrug resistance protein 1 (ABCB1) [1]

• Resistant Disease: Lupus erythematosus [ICD-11: 4A40.0]
• Molecule Alteration: Expression; Up-regulation
• Resistant Drug: Corticosteroids
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Flow cytometry assay
• Mechanism Description: Several studies on patients with systemic autoimmune diseases in particular SLE, RA and PsA have demonstrated a significant correlation between P-gp expression/function, disease activity and the development of resistance to immunosuppressive therapy.

Key Molecule: Multidrug resistance protein 1 (ABCB1) [1]

• Resistant Disease: Lupus erythematosus [ICD-11: 4A40.0]
• Molecule Alteration: Expression; Up-regulation
• Resistant Drug: Corticosteroids
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Flow cytometry assay
• Mechanism Description: Several studies on patients with systemic autoimmune diseases in particular SLE, RA and PsA have demonstrated a significant correlation between P-gp expression/function, disease activity and the development of resistance to immunosuppressive therapy.

References

• Ref 1: P-glycoprotein and drug resistance in systemic autoimmune diseases .Int J Mol Sci. 2014 Mar 20;15(3):4965-76. doi: 10.3390/ijms15034965. 10.3390/ijms15034965